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Previewswithin other malignancies. Quite possibly,
one might uncover other embryonic regu-
lators that also become aberrantly reacti-
vated. Although quiescence serves as
a protective mechanism for Sox2+ tumor
cells, it remains unclear if they also
possess additional strategies that protect
them against insults from other therapeu-
tic agents that act in a different manner.
More comprehensive interrogation of
molecular hallmarks attributed to CSCs
will likely reveal vulnerabilities that could
be targeted with CSC-specific therapies.
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Profound metabolic differences between cancer cells and fibroblasts promote tumorigenesis. A study by
Valencia and colleagues in this issue of Cancer Cell supports this assertion. They observed that metabolic
asymmetry in prostate tumors drives aggressive disease with high p62 in anabolic cancer cells, but loss of
p62 in catabolic fibroblasts.Recent advances in tumor metabolism
have revealed that there are dra-
matic metabolic differences between the
distinct cell types that compose a tumor.
A newly described phenomenon is that
cancer cells metabolically reprogram fi-
broblasts resulting in ‘‘metabolic asym-
metry’’ between cancer cells and fibro-
blasts that promotes tumor growth.
In asymmetric tumor metabolism, can-
cer cells are anabolic due to catabolic
tumor fibroblasts (Martinez-Outschoorn
et al., 2014). Initial studies on meta-
bolic asymmetry were performed in hu-
man breast cancer, but it has also beendemonstrated in ovarian cancer, head
and neck cancer, and lymphomas. It is
now well recognized that metabolic trans-
formation of fibroblasts with increased
catabolism occurs via inflammation and
high levels of reactive oxygen species
(ROS) acting as the second messenger,
and these are critical factors for initiating
tumorigenesis, cancer progression, and
distant metastasis. A new elegant study
inCancer Cell by Valencia et al. (2014) crit-
ically enhances our understanding of this
emerging paradigm in prostate cancer.
Fibroblast catabolic processes such
as autophagy provide the high-energycatabolites (such as L-lactate, ketones,
and glutamine) to the anabolic cancer
cells. Asymmetry of metabolism also oc-
curs between cancer cells and tissues at
a distance, with increased fatty acid gen-
eration in adipose tissue and catabolism
in muscle, in melanoma, and lung cancer
models (Das et al., 2011). Metabolic
asymmetry with catabolic cells sup-
porting anabolic cells can even occur
between different carcinoma cell popula-
tions within a single tumor (Sonveaux
et al., 2008). These examples show that
metabolic asymmetry and energy transfer
occurs in human tumors and that cancerell 26, July 14, 2014 ª2014 Elsevier Inc. 5
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Figure 1. Metabolic Asymmetry:
Compartment-Specific Oncogenes and
Tumor Suppressors
Metabolic asymmetry occurs when catabolic fibro-
blasts favor anabolism in cancer cells and this,
in turn, promotes tumor growth. The functional
activity of oncogenes and tumor suppressors
may be cell-type and compartment specific. HIF-
1a, ATG16L1, UCP1, and p62 are all key examples
of proteins that facilitate metabolic reprogram-
ming. CAFs, cancer-associated fibroblasts; RED,
indicates anabolic cells; YELLOW, indicates cata-
bolic cells.
(A) p62, which induces anabolism, behaves as an
oncogene in prostate cancer cells and acts as a tu-
mor suppressor in cancer-associated fibroblasts.
(B) HIF-1a, ATG16L1, and UCP1, which all induce
catabolism, are oncogenes in cancer-associated
fibroblasts but tumor suppressors in breast cancer
cells.
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Previewscells can exert metabolic effects both
locally and at distant sites.
Fine-tuning of cell signaling and auto-
phagy occurs via the multidomain protein
adaptor p62 that serves as a hub for the
co-localization of signaling molecules.
Loss of p62 is a key marker of autophagy
(Komatsu et al., 2007). The study by
Valencia et al. (2014) establishes loss of
p62 as a marker of metabolic asymme-
try and ‘‘metabolically transformed’’ can-
cer fibroblasts in prostate cancer. They
describe, using in vitro and in vivo
models, how prostate cancer fibroblasts
are reprogrammed via loss of p62 to
have reduced c-Myc and mTOR expres-
sion, leading to high levels of ROS and
catabolism. The increase in ROS conse-
quently drives inflammation via trans-
forming growth factor b (TGF-b) activation
and the release of interleukin-6 (IL-6). This
loss of p62 in fibroblasts is associated
with high p62 expression in carcinoma
cells. Increased p62 expression in epithe-
lial cells occurs with transformation from
normal epithelial cells to carcinoma cells
and with increasing cancer grade, as clin-
ically measured by the Gleason score.
This study highlights that asymmetric
cell signaling and metabolism exists6 Cancer Cell 26, July 14, 2014 ª2014 Elsevibetween two different prostate tumor
compartments: anabolic epithelial cancer
cells and catabolic adjacent cancer-asso-
ciated fibroblasts (Figure 1).
Similar results showing that onco-
genes are compartment-specific have
been observed with HIF-1a, the main
transcription factor activated in hypoxia
to induce glycolysis (Figure 1). HIF-1a
is an oncogene in fibroblasts in breast
tumors where opposite effects are seen
in carcinoma cells (Chiavarina et al.,
2010). ATG16L1, a marker of autophagy,
also has differential effects when overex-
pressed in breast carcinoma cells or in
fibroblasts. It behaves as an oncogene
when overexpressed in fibroblasts but
acts as a tumor suppressor when ex-
pressed in breast carcinoma cells (Cap-
parelli et al., 2012). Virtually identical
results were also obtained with the
mitochondrial uncoupling protein UCP1.
It behaves as a tumor promoter in stro-
mal fibroblasts and as a tumor sup-
pressor in breast cancer epithelial cells
(reviewed in Martinez-Outschoorn et al.,
2014).
Caveolin 1 (Cav-1) expression in fibro-
blasts suppresses tumor growth and
shares features with p62 to induce tumor
metabolic asymmetry. Cav-1 is an inte-
gral member of caveolae that regulates
cell signaling via its many interacting
partners such as nitric oxide synthase
(NOS), Ras, NF-kB, and HIF-1a (Marti-
nez-Outschoorn et al., 2014). For
example, NOS is suppressed by direct
binding to Cav-1, thereby reducing nitra-
tive and oxidative stress. Tumor growth
is dramatically enhanced by loss of fibro-
blast Cav-1 in prostate cancer in the
same way that occurs with loss of p62.
Also, autophagy, oxidative stress, and
inflammation in tumor fibroblasts are
induced by loss of Cav-1, as seen for
p62. Conversely, high Cav-1 and p62 in
cancer cells can both promote tumor
growth (Duran et al., 2011; Martinez-Out-
schoorn et al., 2014).
Valencia et al. (2014) show that
expression of c-Myc is downregulated,
with a loss of p62 in prostate cancer fi-
broblasts. Aggressive prostate cancer is
associated with low c-Myc expression
in fibroblasts. They report downregula-
tion of c-Myc in fibroblasts decreases
glutathione levels and induces IL-6
secretion in fibroblasts, resulting in
cancer cell invasion and proliferation.er Inc.Conversely, c-Myc overexpression in
p62 knockout fibroblasts reduces IL-6
levels. In contrast to cancer fibroblasts,
prostate carcinoma cells commonly
have c-Myc overexpression associated
with aggressive disease (Bernard et al.,
2003). Differential expression of c-Myc
in fibroblast and epithelial tumor cell
compartments therefore highlights the
existence of asymmetry within these
tumors. It is conceivable that c-Myc is
an oncogene or a tumor suppressor de-
pending on the tumor compartment in
which it is highly expressed, but this
needs to be formally tested.
This study indicates how it is crucial to
study each tumor compartment indepen-
dently when studying cancer metabolism
and cell signaling to avoid incorrect con-
clusions. If no further characterization of
the tumor stroma had been performed
after the initial studies of p62 in prostate
cancer cells, we would have incomplete
information and erroneously concluded
that p62 is an oncogene in prostate
cancer.
However, the study by Valencia et al.
(2014) does not provide information on
how cancer cells reprogram fibroblasts
to induce p62 loss and metabolic asym-
metry. Others have demonstrated that
high oxidative stress generated by
cancer cells leads to metabolic reprog-
ramming of fibroblasts that is self-
perpetuating and amplified further by
downstream inflammatory effects. These
downstream effectors of oxidative stress
include activation of TGF-b, HIF-1a, and
NF-kB with the release of the inflamma-
tory cytokines IL-6 and IL-8. It will be
important to determine if the drivers of
fibroblast metabolic reprogramming and
metabolic asymmetry in prostate cancer
are similar to those seen in other cancer
subtypes.
Identifying key drivers of asymmetric
tumor metabolism will be necessary to
therapeutically exploit the metabolic dif-
ferences that occur between cancer cells
and stromal fibroblasts. Recent mathe-
matical modeling of this ‘‘metabolic-sym-
biosis’’ or asymmetry indicates that inhi-
bition of energy transfer, from fibroblasts
to cancer cells, is a valid strategy for
designing new targeted anticancer thera-
pies (Kianercy et al., 2014). ‘‘Reversal’’ or
‘‘normalization’’ of metabolic asymmetry
therefore may allow us to effectively
inhibit tumor growth with less toxicity
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Previewsthan conventional therapies. Also, target-
ing fibroblast-cancer cell interactions, by
focusing on ‘‘reversing metabolic asym-
metry,’’ may be a more widely applicable
and successful chemotherapy strategy
for personalized medicine than trying to
develop specific treatments for each in-
dividual molecular target and histologic
subtype of cancer.REFERENCES
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In this issue of Cancer Cell, Vora and colleagues demonstrate that persistent CDK4 and pRB activation
underlie acquired resistance to phosphatidylinositol 3-kinase (PI3K) inhibitors in breast cancer cell lines, sug-
gesting that clinical evaluation of rational combination therapy with PI3K and CDK4/6 inhibitors to mitigate
resistance to PI3K inhibition is warranted.Phosphatidylinositol 3-kinase (PI3K)
regulates cellular proliferation, survival,
and metabolism. PI3K pathway activation
due to aberrant upstream signaling or
mutation of pathway components occurs
in more cancers than any other cellular
signaling pathway. The PIK3CA gene
that encodes the catalytic subunit of
PI3Ka, p110a, is mutated in almost 40%
of breast cancers, and if mutations in
other pathway members that lead to
increased PI3K signaling are included
(e.g., PTEN, PIK3R1-3 and AKT1-3),
more than half of all breast cancers have
at least one PI3K pathway aberration. In
addition, activation of upstream recep-
tor tyrosine kinases, such as occurs
in HER2-positive breast cancers, leads
to increased PI3K signaling. Consistent
with a dependency on PI3K pathwaysignaling, the efficacy of HER2-targeted
therapy is limited by concurrent PI3K
pathway mutations. Similarly, relapse of
estrogen receptor (ER) positive breast
cancers is often associated with constitu-
tive PI3K pathway activation. This has
driven interest in implementing inhibitors
targeting the PI3K pathway into the breast
cancer drug armamentarium. Indeed,
multiple clinical trials are currently evalu-
ating the efficacy of over 30 drugs target-
ing different nodes in the PI3K pathway
in breast and other cancers (https://
clinicaltrials.gov). However, to date, re-
sponses of solid tumors to monotherapy
have been modest and accompanied by
rapid emergence of drug resistance.
The overarching goal for the elucidation
of resistance mechanisms is to facilitate
implementation of rational combinationtherapies that will overcome or prevent
emergence of resistance. Indeed, combi-
nation strategies are beginning to fulfill
the initial excitement that accompanied
the development of PI3K pathway inhibi-
tors. Combination approaches follow two
different strategies. The first approach is
aimed at overcomingPI3Kpathway-medi-
ated resistance to therapeutics targeting
other pathways. For example, combina-
tions of PI3K pathway inhibitors with hor-
mone responsemodifiers in luminal breast
cancer have demonstrated exciting activ-
ity, and, indeed, the allostericmTOR inhib-
itor everolimus has been approved in
combination with the aromatase inhibitor
exemestane for treatment of postmeno-
pausal women with advanced hormone-
receptor positive, HER2-negative breast
cancer (Baselga et al., 2012). A numberell 26, July 14, 2014 ª2014 Elsevier Inc. 7
